EditorialStrategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs
Section snippets
Conclusions
This is an exciting era for the field of HCV. As newer IFN-free DAA agents become available, strategies to address HCV infection among PWID will need to be integrated into existing foundations for prevention and health care for PWID, in partnership with the affected community and with a commitment to tackling stigma and discrimination associated with injecting drug use and HCV. However, as we move forward, and as the themed papers in this issue highlight, it will be important to consider how
Financial support
The Kirby Institute and the Centre for Social Research in Health are funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. JG is supported by a National Health and Medical Research Council Career Development Fellowship. GD is supported by a National Health and Medical Research Council Practitioner Research Fellowships.
Disclosures
JG is a consultant/advisor and has received research grants from Abbvie, Bristol Myers Squibb, Gilead Sciences and Merck. GD is a consultant/advisor and has received research grants from Abbvie, Bristol Myers Squibb, Gilead, Merck, Janssen and Roche. PB is consultant/advisor and has received research grants from Abbvie, Bristol Myers Squibb, Gilead, Janssen and Merck.
References (30)
- et al.
Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C
International Journal of Drug Policy
(2015) - et al.
Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention
International Journal of Drug Policy
(2015) - et al.
Global policy and access to new hepatitis C therapies for people who inject drugs
International Journal of Drug Policy
(2015) - et al.
Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries
International Journal of Drug Policy
(2015) - et al.
Harm reduction theory: users’ culture, micro-social indigenous harm reduction, and the self-organization and outside-organizing of users’ groups
International Journal of Drug Policy
(2007) - et al.
Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs
International Journal of Drug Policy
(2015) - et al.
Recommendations for the management of hepatitis C virus infection among people who inject drugs
International Journal of Drug Policy
(2015) - et al.
The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs?
International Journal of Drug Policy
(2015) - et al.
Hepatitis C transmission and treatment as prevention – The role of the injecting network
International Journal of Drug Policy
(2015) - et al.
Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland's experience
International Journal of Drug Policy
(2015)